IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.
Hundertmark MJ, Birkhoelzer SM, Portwood C, Siu AG, Matthews V, Lewis AJ, Grist J, Mózes F, Henry JA, Patel J, Chamberlin P, Sarwar R, Yavari A, Dehbi HM, Rao P, Shi X, Zheng S, Robbins JM, Gerszten RE, Frenneaux MP, Valkovič L, Miller JJJJ, Neubauer S, Tyler DJ, Rider OJ.
Hundertmark MJ, et al.
Circulation. 2026 Feb 24;153(8):550-563. doi: 10.1161/CIRCULATIONAHA.125.074041. Epub 2025 Dec 18.
Circulation. 2026.
PMID: 41410037
Free PMC article.
Clinical Trial.
Consistently, treatment with ninerafaxstat was associated with improvement in PCr/ATP (+0.150.25 [95% CI, 0.03-0.26]; Cohen's d, 0.60; P=0.02), improved systolic augmentation to exercise (+1.4 L/min, P=0.04), improved exercise capacity (6-minute walk distance +16 m, P=0.02 …
Consistently, treatment with ninerafaxstat was associated with improvement in PCr/ATP (+0.150.25 [95% CI, 0.03-0.26]; Cohen's d, 0.60; P=0.0 …